Ga-68 DOTATOC PET/CT changed the therapeutic course of a patient with the sudden onset of vision problems

Clinical Nuclear Medicine

Volumn 34, Issue 1, 2009, Pages 27-28

  Van Riet, Jelle ^a   Rattat, Dirk ^b   Verbruggen, Alfons ^b   Mortelmans, Luc ^a   Mottaghy, Felix M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Ga 68 DOTATOC; Lu 177 DOTATATE; Neuroendocrine tumors; PET CT; Somatostatin analogue

Indexed keywords

[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYR 3 ]OCTREOTATE LU 177; [1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE(3)] OCTREOTIDE GA 68; CHROMOGRANIN; FLUORODEOXYGLUCOSE; GALLIUM 68; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; (DOTA(0) PHE(1) TYR(3))OCTREOTIDE; (DOTA(0)-PHE(1)-TYR(3))OCTREOTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GALLIUM; OCTREOTIDE;

ADULT; ARTICLE; BLURRED VISION; BRONCHUS CARCINOID; CASE REPORT; CHOROID MELANOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; EYE INJURY; FOLLOW UP; HISTORY; HUMAN; LIVER; MALE; MEDIASTINUM; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOLOGY; PANCREAS; PATHOLOGICAL ANATOMY; TUMOR LOCALIZATION; VISUAL DISORDER; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING;

GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; VISION DISORDERS;

EID: 59649092454     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31818f4588     Document Type: Article

References (8)

1. Strobel K, Dummer R, Husarik DB, et al. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology. 2007;244:566-574.
2. Hofmann M, Maecke H, Bö;rner AR, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand Ga-68 DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-1757.
3. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendo-crine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
4. Reubi JC, Schär JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scinti-graphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282.
5. Mottaghy FM, Reske SN. Functional imaging of neuroendocrine tumours with PET. Pituitary. 2006;9:237-242.
6. Van Essen M, Krenning EP, De Jong M, et al. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46:723-734.
7. Esser JP, Krenning EP, Teunissen JJ, et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur JNucl Med Mol Imaging. 2006;33:1346-1351.
8. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405-422.